p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer

The Lancet

Volumn 345, Issue 8955, 1995, Pages 994-

  Runnebaum, I B ^a   Tong, X W ^b,c   Konig R ^b,c   Hong, Z ^b,c   Korner K ^b,c   Atkinson, E N ^b,c   Kreienberg, R ^b,c   Kieback, D G ^b,c  

^a UNIVERSITY OF ULM   (Germany)

^b Department of Transfusion Medicine   (Germany)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P53; TUMOR MARKER;

BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSIS; DNA POLYMORPHISM; EARLY DIAGNOSIS; FEMALE; GENE FREQUENCY; GENE INSERTION; HUMAN; HUMAN CELL; LETTER; LEUKOCYTE; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0028905769     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(95)90745-9     Document Type: Letter

References (4)

1. BRCA1 mutations in primary breast and ovarian carcinomas
2. Mutations in p53 as potential molecular markers for human breast cancer
3. Multiplex PCR (MPCR) screening detects small p53 deletions and insertions in human ovarian cancer cell lines
4. Simple sequence repeat polymorphism within the p53 gene